-
Lyso-Tracker Red for Reliable Lysosome Assays
2026-09-18
Learn how Lyso-Tracker Red, SKU B8814, supports reproducible lysosome labeling in live-cell viability, cytotoxicity, and nanoparticle studies. This scenario-based guide covers probe selection, protocol parameters, interpretation limits, and vendor reliability.
-
Dynamic Myelin Remodeling After CNS Damage
2026-09-18
A 2026 Science study shows that early CNS myelin damage often appears as swelling that can resolve or remodel rather than inevitably progressing to sheath loss. By linking activity-dependent pathology across zebrafish, rodent, and human MS tissue, the work identifies a potentially actionable window before irreversible demyelination.
-
EZ Cap™ Mouse CD252(OX40L) mRNA Guide
2026-09-17
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) is a research-use mouse OX40L construct with an HA epitope tag and N1-methylpseudouridine chemistry. R1078 supports controlled studies of ligand expression, receptor engagement, and immune co-stimulation, but the cited antitumor study tested CD80 and 4-1BBL mRNAs rather than OX40L.
-
5-Methyl-CTP for Better mRNA Workflows
2026-09-17
Learn how 5-Methyl-CTP can be integrated into controlled in vitro transcription workflows to investigate enhanced mRNA stability and improved mRNA translation efficiency. The article also connects nucleotide engineering with the OMV-based antigen-display strategy reported for personalized tumor vaccination, while clearly separating demonstrated findings from practical optimization ideas.
-
Making mRNA Delivery Measurable with Dual Fluorescence
2026-09-16
Dual fluorescence turns mRNA delivery into a measurable chain of events: cellular uptake, intracellular handling, and functional translation. This article connects Cap 1 and 5-moUTP design with RNA-vector morphology to guide translational assay development.
-
Thiothixene: From D2 Blockade to Precision Research
2026-09-15
Thiothixene is a typical antipsychotic agent with applications spanning dopamine receptor pharmacology and macrophage biology. This evidence-focused guide connects its efferocytosis activity with emerging schizophrenia target discovery while clarifying assay design, translational relevance, and scientific limitations.
-
Platelet Extravasation and Tumor Growth Control
2026-09-15
The reference study defines platelet transendothelial migration into tumors as a regulated process controlled by CXCL12/CXCR4 signaling, FAK, PECAM-1, and the CLEC-2/podoplanin vascular pathway. Its most important conceptual advance is separating platelet trafficking from platelet effector activity, showing that distinct granule-release programs can either promote tumor growth or preserve vascular integrity.
-
Naloxone Hydrochloride: From Blockade to Translation
2026-09-14
Naloxone hydrochloride is more than a standard opioid receptor antagonist: it can serve as a mechanistic control across receptor signaling, neural stem cell, immune, and behavioral workflows. This translational guide connects assay design, product quality, and cross-domain drug-discovery strategy without confusing research evidence with clinical conclusions.
-
Gamithromycin PK/PD in Bovine Respiratory Disease
2026-09-14
This prospective clinical study linked gamithromycin exposure with treatment outcome in cattle with naturally occurring bovine respiratory disease, emphasizing pulmonary epithelial lining fluid as a pharmacologically relevant effect compartment. Its modeling strategy shows why site-of-infection PK/PD indices can provide more useful response predictions than plasma measurements alone.
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-09-13
The 2026 reference study identifies ALDOB K87 lactylation as a mechanistic link between hypoxia-associated glycolytic rewiring, mitochondrial fission, and pulmonary vascular remodeling. Its lactate–ALDOB–DRP1 axis provides a framework for studying how nonhistone post-translational modifications regulate pulmonary artery smooth muscle cell behavior.
-
Dabigatran: Mechanism, Evidence, and Research Use
2026-09-12
Dabigatran is a reversible direct thrombin inhibitor that blocks both free and fibrin-bound thrombin. As Pradaxa, it has established clinical roles in stroke prevention in atrial fibrillation and venous thrombosis treatment, while research-grade material supports thrombin inhibition assays and coagulation function tests.
-
WNT-Driven Bile Duct Proliferation After Obstruction
2026-09-12
Calder and colleagues show that obstruction-induced proliferation in the mouse extrahepatic bile duct is linked to locally activated, β-catenin-dependent WNT signaling. By combining bile duct ligation with mouse and human biliary organoids, explants, pharmacologic pathway modulation, and transcriptomic analysis, the study identifies cholangiocyte-derived WNT ligands, including WNT7B, as contributors to the injury response.
-
Betulinic Acid, ERK, and Cyclophosphamide Liver Injury
2026-09-11
This 2025 mouse study identifies ERK-linked mitochondrial apoptosis as an important component of cyclophosphamide-induced oxidative liver damage and shows that betulinic acid attenuates this injury. Its combined use of antioxidant, mitochondrial, apoptotic, and pharmacological pathway readouts offers a useful framework for evaluating hepatoprotective mechanisms, while remaining preclinical.
-
Doxorubicin Workflows for Cardiotoxicity Research
2026-09-11
Build reproducible Doxorubicin assays that connect tumor-cell killing with oxidative stress, autophagy, apoptosis, and cardiac safety readouts. This workflow translates the aucubin–NRF2–HIPK2 findings into practical paired cancer and cardiotoxicity experiments.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-10
Borchert et al. linked homologous recombination repair defects, including BAP1-associated BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their combined cell-line and clinical gene-expression strategy identifies a rationale for PARP inhibition, particularly with cisplatin, while also clarifying why these findings remain hypothesis-generating rather than clinically validated.